Natco Pharma Limited has informed the Exchange about Transcript
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma is proposing to acquire a 35.75% stake in Adcock Ingram Holdings, the second-largest private pharma company in South Africa, for approximately ₹2,000 crores. Bidvest will retain the remaining 64.25% and the company will be delisted from South African exchanges. Adcock does around $536 million in annual revenue, which will push Natco's group revenue close to $1 billion. The deal is being funded largely from Natco's cash reserves (₹3,500 crores currently on books, ~₹1,500 crores expected to remain post-deal), with transaction closure expected in 3-4 months. Natco will consolidate 35.75% of Adcock's profits into its P&L and has secured one-third board representation. Management sees strong synergies from introducing Natco's complex generics pipeline into Adcock's South African distribution network and also plans to leverage Adcock's PIC/S-approved plants for exports.
This is Natco's largest-ever acquisition and a significant diversification move to reduce its heavy dependence on the US market, which should be viewed positively by investors. The deal is expected to be earnings-accretive immediately through profit consolidation, with longer-term margin improvement as Natco's pipeline is integrated into Adcock's portfolio over the next 2-3 years.